We are discovery rich, but development poor

We Are Discovery Rich, But Development Poor: A Candid Conversation with Dr. Reddy's Laboratories' Co-Chairman and Managing Director, G.V. Prasad

In a candid conversation with ET's pharma editor, Vikas Dandekar, on Corner Office Conversation, G.V. Prasad, Co-Chairman and Managing Director of Dr. Reddy's Laboratories, shares his insights on the company's journey, highlighting the opportunities missed, potential and challenges that lie ahead. With over thirty years at the helm, Prasad reflects on the regulatory crises weathered, acquisitions never made, and an innovation pipeline that remained perpetually underfunded. In this article, we delve into the conversation, exploring the company's next act and its plans for innovation-led growth.

India: The Generic Pharmacy of the World

Prasad emphasizes that India is the generic pharmacy of the world, not the pharmacy of the world. This distinction matters, as it highlights the country's strength in producing high-quality generic drugs at competitive prices. However, he also acknowledges that the industry has been plagued by regulatory crises, which have hindered growth and innovation.

Missed Opportunities: A Look Back

Prasad reflects on the opportunities that were missed, including acquisitions that could have driven growth and innovation. He notes that the company has been slow to adapt to changing market conditions, citing the example of the biosimilars market, where Dr. Reddy's Laboratories was late to the party.

Regulatory Crises: Weathered but Not Forgotten

Prasad discusses the regulatory crises that the company has faced, including the US FDA's inspections and enforcement actions. He emphasizes that the company has weathered these crises, but the experience has highlighted the need for greater regulatory clarity and predictability.

Innovation Pipeline: Underfunded and Underutilized

Prasad acknowledges that the company's innovation pipeline has remained perpetually underfunded and underutilized. He notes that the company has been slow to invest in research and development, which has hindered its ability to develop new products and stay ahead of the competition.

Artificial Intelligence: Helpful at the Margins, Not Yet Transformational

On the topic of artificial intelligence (AI), Prasad is deliberately unsentimental. He acknowledges that AI is helpful at the margins, but notes that it is not yet transformational. He emphasizes that the company is focused on leveraging AI to improve operational efficiency, rather than relying on it to drive innovation.

The Next Act: A Decisive Pivot to Innovation-Led Growth

Prasad stresses the need for a decisive pivot from incremental generics to innovation-led growth. He notes that the company has set a hard target for innovation-led growth and is working towards achieving it. He emphasizes that the company needs to focus on developing new products and staying ahead of the competition.

Conclusion: A Call to Action

In conclusion, Prasad's candid conversation with ET's pharma editor highlights the opportunities missed, potential and challenges that lie ahead for Dr. Reddy's Laboratories. The company's next act is a decisive pivot from incremental generics to innovation-led growth, with a hard target and a ticking clock. As the company navigates this shift, it will need to focus on developing new products, investing in research and development, and leveraging technology to improve operational efficiency.

Analysis

Dr. Reddy's Laboratories has been a dominant player in the generics market, but the company's lack of investment in innovation has hindered its ability to stay ahead of the competition. The company's next act is a decisive pivot to innovation-led growth, which will require a significant shift in focus and resources. The company's hard target for innovation-led growth is a welcome development, but it will need to be accompanied by a sustained commitment to research and development.

Recommendations

To achieve its innovation-led growth target, Dr. Reddy's Laboratories should focus on the following:

1. Invest in Research and Development: The company should increase its investment in research and development, focusing on developing new products and staying ahead of the competition.
2. Leverage Technology: The company should leverage technology to improve operational efficiency, including the use of artificial intelligence and data analytics.
3. Develop a Strong Pipeline: The company should focus on developing a strong pipeline of new products, including biosimilars, generic drugs, and innovative therapies.
4. Enhance Regulatory Clarity and Predictability: The company should work towards enhancing regulatory clarity and predictability, which will help to reduce uncertainty and improve its ability to plan and invest for the future.

By following these recommendations, Dr. Reddy's Laboratories can overcome its current challenges and achieve its goal of becoming a leader in innovation-led growth.